Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Courtnee A CloughDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0002-7859-7252
Claire CunninghamDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Sophia Y PhilbrookDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0009-0004-6973-902X
Kathleen M HuenemanDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Avery M SampsonDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0001-7241-8770
Kwangmin ChoiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0003-4671-962X
Kenneth D GreisDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA.ORCID 0000-0002-5316-3351
Daniel StarczynowskiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. daniel.starczynowski@cchmc.org.ORCID 0000-0002-5771-7462
Funding
Xenotransplant and Genome Editing CoreU54DK126108 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Daniel Starczynowski, YI ZHENG · 2021 to 2026
$5.0M
Decoding innate immune signaling in normal and myelodysplastic hematopoiesisR35HL166430 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Daniel Starczynowski · 2023 to 2026
$4.3M
Dissecting innate immune signaling in pre-leukemia evolutionR01CA271455 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Iannis Aifantis, Daniel Starczynowski · 2022 to 2026
$3.2M
Therapeutic targeting of IRAK4 in MDSR01CA275007 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Daniel Starczynowski, Amit K. Verma · 2022 to 2026
$2.6M
Post-Graduate Hematology/Oncology Translational (PG-HOT) Training ProgramT32CA236764 · NCI · UNIVERSITY OF CINCINNATI · PI QI, XIAOYANG, SCAGLIONI, PIER PAOLO · 2019 to 2023
$2.1M
An Orbitrap Mass Spectrometry System for the University of Cincinnati Proteomics LaboratoryS10OD026717 · OD · UNIVERSITY OF CINCINNATI · PI GREIS, KENNETH DONALD · 2019 to 2019
VEXAS syndrome is a clonal hematopoietic disorder characterized by hyperinflammation, bone marrow failure, and high mortality. The molecular hallmark of VEXAS is somatic mutations at methionine 41 (M41) in the E1 ubiquitin enzyme, UBA1. These mutations induce a protein isoform switch, but the mechanisms underlying disease pathogenesis remain unclear. Here, we developed a human cell model of VEXAS syndrome by engineering the male monocytic THP1 cell line to express the common UBA1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome. · full record | Socratic